Caladrius Biosciences to Present at the Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day

Caladrius Biosciences to Present at the Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day

March 11, 2019

BASKING RIDGE, N.J. (March 11, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select cardiovascular indications, announced today that David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Biosciences, will present at the Alliance for Regenerative Medicine (ARM) 7th Annual Cell & Gene Therapy Investor Day.

The following are specific details regarding Dr. Mazzo’s presentation:

Event:                                 ARM’s Cell & Gene Therapy Investor Day
Date & Time:                     Thursday, March 21, 2019 at 4:45 p.m. (ET)
Room:                                 West Lounge Room
Venue:                                Metropolitan Club in New York, NY

Dr. Mazzo’s presentation will be webcast live and available for replay on the Alliance for Regenerative Medicine event website: www.arminvestorday.com/webcast.

About Caladrius Biosciences

Caladrius is a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. The Company’s goal is to build a broad portfolio of novel and versatile products that address important unmet medical needs. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34 cell therapy platform: CLBS12, recipient of SAKIGAKE designation, in Phase 2 testing in Japan and eligible for early conditional approval for the treatment of critical limb ischemia; CLBS14-CMD, in Phase 2 testing for the treatment of coronary microvascular dysfunction; and CLBS14-NORDA (formerly CLBS14-RfA) in late-stage development for no option refractory disabling angina for which it has received RMAT designation. For more information on the company, please visit www.caladrius.com.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone:  +1-908-842-0084
Email: jmenditto@caladrius.com